Sentences with phrase «docetaxel in»

Comparative benefits of Nab - paclitaxel over gemcitabine or polysorbate - based docetaxel in experimental pancreatic cancer.

CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.

No evaluable data were available for the comparison with docetaxel in patients in whom prolongation of life was the primary treatment goal.

The researchers showed that cabazitaxel worked better than docetaxel in human prostate cancer cells lines that were resistant hormone treatment, both in terms of slowing cancer - cell growth and in its ability to kill cancer cells.

If prolongation of life was the primary therapeutic objective and the patients were eligible for docetaxel treatment, the G - BA specified docetaxel in combination with prednisone or prednisolone as appropriate comparator therapy (docetaxel population).

Not exact matches

Findings were presented at the WCLC are based on the updated results of 12 lung cancer patients enrolled in the clinical trial with pembro and irinotecan or gemcitabine with or without vinorelbine or docetaxel.

The next generation drug in the taxane family, cabazitaxel, was approved in 2010, but only for patients whose cancer no longer responded to hormone therapy or docetaxel treatment.

Analysis of the tumor genes affected by the two drugs revealed that cabazitaxel had a greater effect on cellular division and regulation of chromatin — a spool for DNA that helps control which genes are in use and when — whereas docetaxel has a greater impact on DNA transcription and repair.

This was offset by a hint of considerably greater harm from radium - 223 + BSC due to more frequent, but never severe, diarrhea in patients without docetaxel pretreatment.

It was assumed in the assessment that most of the remaining patients actively decided against docetaxel treatment.

The majority of patients included in the study were not eligible for docetaxel because their disease had progressed despite pretreatment with this drug (approximately 57 %).

Researchers from BIND Biosciences in Boston filled nanoparticles with the cancer drug docetaxel and injected them into the blood of 17 people who had cancers that are normally resistant to the drug.

Results also showed 27.7 percent of patients in the ADT plus docetaxel arm had a decline in prostate specific antigen (PSA) to less than 0.2 ng / mL at 12 months compared with 16.8 percent for those taking ADT alone.

«When we embarked on this study, early clinical trials and laboratory studies supported the possibility (or hypothesis) that earlier therapy in appropriate patients with docetaxel, used in combination before hormonal resistance occurred, could have greater benefit, but required proof in a definitive study.

Research coordinated by the ECOG - ACRIN Cancer Research Group, supported in part by the National Cancer Institute, and published in the current online version of The New England Journal of Medicine, examined the outcomes of giving the chemotherapy drug docetaxel at the start of ADT.

In the ADT - plus - docetaxel group, 45 patients whose disease progressed received additional docetaxel.

The addition of docetaxel not only lengthened survival but delayed disease progression as measured by an increase in prostate - specific antigen (PSA), the appearance of new metastases, or worsening symptoms.

In the ADT - only group, 124 patients were given docetaxel when their cancer worsened.

In the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 monthIn the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 monthin the ADT - only group — a difference of 17 months.

The new analysis extends follow - up significantly; it includes 790 patients randomized to either ADT alone (393 patients) or in combination with docetaxel (397 patients).

Long - term follow - up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival (OS) over ADT alone in metastatic hormone - sensitive prostate cancer (mHSPC) patients with high - volume disease.

«Biomarkers determining who will or will not completely respond to neoadjuvant TCHP [trastuzumab, carboplatin, docetaxel, and pertuzumab] are lacking,» wrote study authors led by Jeremy Force, DO, of Duke University School of Medicine in Durham, North Carolina.

Disease - free survival was similar in the 9 - week and 12 - month arms among those patients who received 100 mg / m2 docetaxel.

«In all the subgroups we tested the longer arm tended to be better than the shorter one, but we did detect an interaction between docetaxel dose and disease - free survival,» Joensuu said.

In contrast, among those who received 80 mg / m2 docetaxel, 12 months of trastuzumab had superior disease - free survival.

The trial actually enrolled 938 patients with recurrent advanced NSCLC; physicians initially chose pemetrexed or docetaxel for patients, after which patients were randomized to either chemotherapy alone or in addition to a cetuximab regimen.

The main purpose of this study is to find out more about the side effects of the study drug, MM - 121, when combined with the study drugs, docetaxel or pemetrexed, and to learn if cancer cell growth (disease progression) is delayed in people taking MM - 121 with docetaxel or pemetrexed.

Researchers are also trying to learn about: - The level of MM - 121 that remains in the human body at different time points when MM - 121 is combined with docetaxel or pemetrexed - The relationship between the biomarker, heregulin, and cancer cell growth (disease progression) in people dosed only with docetaxel or pemetrexed.

Patient 2 was diagnosed with widespread metastatic prostate cancer in 2013 and progressed on numerous systemic therapies, including leuprolide, bicalutamide, enzalutamide, abiraterone, and eventually docetaxel.

CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.

The median age of patients was similar between the two groups, at 67 in the docetaxel group and 66 in the erlotinib group.

Almost 72 % of docetaxel patients were current or former smokers, compared with 81.7 % in the erlotinib group.

There was one treatment - related death in the erlotinib group, and 22.1 % of docetaxel patients and 29.0 % of erlotinib patients suffered adverse events that led to dose modification.

The hazard ratio for progression - free survival was 0.69 in favor of docetaxel (95 % CI, 0.52 — 0.93; P =.014).

The drug's manufacturer, Roche, said trials in these patients have shown that giving pertuzumab in combination with the drugs trastuzumab (Herceptin) and docetaxel could extend survival by nearly 16 months compared to standard treatment.

Pertuzumab was approved by the FDA in 2012 for first - line treatment of HER2 + metastatic breast cancer in combination with trastuzumab and the chemotherapy docetaxel (Taxotere).

In 2014, researchers at the National Cancer Conference made the following statement: «Long term significant scalp alopecia (here lasting for up to 3.5 years following completion of chemotherapy) may affect 10 - 15 % of patients following docetaxel for EBC [early breast cancer].